- Home
- AGMH vs ARTL Comparison
AGMH vs ARTL Comparison
Compare AGMH & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- ARTL
- Stock Information
- Founded
- AGMH 2015
- ARTL 2011
- Country
- AGMH Hong Kong
- ARTL United States
- Employees
- AGMH N/A
- ARTL N/A
- Industry
- AGMH EDP Services
- ARTL Biotechnology: Pharmaceutical Preparations
- Sector
- AGMH Technology
- ARTL Health Care
- Exchange
- AGMH Nasdaq
- ARTL Nasdaq
- Market Cap
- AGMH 3.5M
- ARTL 3.1M
- IPO Year
- AGMH 2018
- ARTL N/A
- Fundamental
- Price
- AGMH $3.11
- ARTL $1.12
- Analyst Decision
- AGMH
- ARTL Strong Buy
- Analyst Count
- AGMH 0
- ARTL 2
- Target Price
- AGMH N/A
- ARTL $5.50
- AVG Volume (30 Days)
- AGMH 857.7K
- ARTL 50.9K
- Earning Date
- AGMH 06-18-2025
- ARTL 05-13-2025
- Dividend Yield
- AGMH N/A
- ARTL N/A
- EPS Growth
- AGMH N/A
- ARTL N/A
- EPS
- AGMH 6.43
- ARTL N/A
- Revenue
- AGMH $32,044,575.00
- ARTL N/A
- Revenue This Year
- AGMH N/A
- ARTL N/A
- Revenue Next Year
- AGMH N/A
- ARTL N/A
- P/E Ratio
- AGMH $0.44
- ARTL N/A
- Revenue Growth
- AGMH N/A
- ARTL N/A
- 52 Week Low
- AGMH $1.09
- ARTL $0.82
- 52 Week High
- AGMH $109.50
- ARTL $1.55
- Technical
- Relative Strength Index (RSI)
- AGMH 44.31
- ARTL 63.75
- Support Level
- AGMH $2.11
- ARTL $1.01
- Resistance Level
- AGMH $4.93
- ARTL $1.14
- Average True Range (ATR)
- AGMH 0.67
- ARTL 0.07
- MACD
- AGMH 0.00
- ARTL 0.02
- Stochastic Oscillator
- AGMH 35.46
- ARTL 91.60
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an investment holding company. The company focuses on blockchain-oriented ASIC chip design; high-end crypto miner production and fintech technology software service. It generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About ARTL Artelo Biosciences Inc.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.